8:26pm PDT - July 31st, 2021

Gantenerumab failed in two trials. One of prodromal AD https://t.co/csiYbS7yFv and the other in Dominantly inherited AD https://t.co/D5zICRMUYQ Despite the clear null result in both trials Roche is now "talking to @US_FDA https://t.co/6VQ4cw4VZz https://t.co/noK8md4i0D

1 retweets   0 likes  - Madhav Thambisetty (@MadhavThambiset)